References
- Chaffman, M. and Brogden, R. N. : Diltiazem: a review of its pharmacological properties and therapeutic efficacy. Drugs. 29, 387 (1985) https://doi.org/10.2165/00003495-198529050-00001
- Weir, M. R. : Diltiazem ten years of clinical experience in the treatment of hypertension. J. Clin. Pharmacol. 35, 220 (1995) https://doi.org/10.1002/j.1552-4604.1995.tb04051.x
- Yeung, P. K., Prescott, C., Haddad, C., Montague, T. J., McGregor, C., Quilliam, M. A., Xei, M., Li, R., Farmer, P. and Klassen, G. A. : Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose. Eur. J. Drug. Metab. Pharmacokinet. 18, 199 (1993) https://doi.org/10.1007/BF03188796
- Scholz, H. : Pharmacological aspects of calcium channel blockers. Cardiovas. Drugs Ther. 10, 869 (1997) https://doi.org/10.1007/BF00051613
- Epstein, M., Loutzenhister, R. D. : Effects of calcium antagonists on renal hemodynamics. Am. J. Kidney Dis. 16, 10 (1990)
- Ruilope, L. M. and Alcaar, J. M. : Renal effects of calcium entry blockers. Cardiovas. Drugs Ther. 4, 979 (1990) https://doi.org/10.1007/BF02018304
- Sterzel, P. B. : Renal actions of calcium antagonists. J. Cardiovas. Pharmacol. 10, 17 (1987) https://doi.org/10.1097/00005344-198706107-00004
- Eichelbaum, M. and Echizen, H. : Clinical pharmacology of calcium antagonists: A critical review. J. Cardiovas. Pharmacol. 6, 963 (1984) https://doi.org/10.1097/00005344-198400067-00006
- Bianchetti, G., Regazzi, M., Rondanelli, R., Ascalone, V. and Morselli, P. L. : Bioavailability of diltiazem as a function of the administered dose. Biopharm. Drug Dispos. 12, 391 (1991) https://doi.org/10.1002/bdd.2510120508
- Klaassen, C. D. : Toxicology. 5th ed. New York: McGraw-Hill. 113 (1999)
- Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T. and Guzelian, P. S. : Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80, 1029 (1987) https://doi.org/10.1172/JCI113156
- Kolars, J. C., Schmiedlin-Ren, P., Dobbins, W. O. 3rd., Schuetz, J., Wrighton, S. A. and Watkins, P. B. : Heterogeneity of cytochrome P450IIIA expression in rat. gut epithelia. Gastroenterology 102, 1186 (1992) https://doi.org/10.1016/0016-5085(92)90756-O
- Lefebvre, M., Homsy, W., Caille, G. and du Souich, P. : Firstpass metabolism of diltiazem in anesthetized rabbits: Role of extrahepatic organs. Pharm. Res. 13, 124 (1996) https://doi.org/10.1023/A:1016097805003
- Homsy, W., Caille, G. and du Souich, P. : The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit. Pharm. Res. 12, 1722 (1995) https://doi.org/10.1023/A:1016217822770
- Homsy, W., Lefebvre, M., Caille, G. and du Souich, P. : Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits: In vitro studies. Pharm. Res. 12, 609 (1995) https://doi.org/10.1023/A:1016226601988
- Yusa, K. and Tsuruo, T. : Reversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to Pglycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49, 5002 (1989)
- Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. : P-glycoprotein-mediated transcellular transport of MDRreversing agents. FEBS Lett. 324, 99 (1993) https://doi.org/10.1016/0014-5793(93)81540-G
- Chaudhary, P. M. and Robinson, I. B. : Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 66, 85 (1991) https://doi.org/10.1016/0092-8674(91)90141-K
- Van Asperen, J., Van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijen, W. J. and Beijnen, J. H. : Enhanced oral bilavailability of diltiazem in mice treated with the pglycoprotein blocker SDZ PSC 833. Br. J. Cancer 76, 1181 (1997) https://doi.org/10.1038/bjc.1997.530
- Biedler, J. L. and Riehm, H. : Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30, 1174 (1970)
- Ford, J. M. : Modulators of multidrug resistancepreclinical studies. Hematol. Oncol. Clin. N. Am. 9, 337 (1995)
- Fruehauf, J. P. and Manetta, A. : Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDR1 expression. Contrib. Gynecol. Obstet. 19, 39 (1994)
- Plosker, G. L. and Wagstaff, A. J. : Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs. 51, 433 (1996) https://doi.org/10.2165/00003495-199651030-00011
- Schectman, G. and Hiatt, J. : Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann. Intern. Med. 125, 990 (1996) https://doi.org/10.7326/0003-4819-125-12-199612150-00011
- Langtry, H. D. and Markham, A. : Fluvastatin: a review of its use in lipid disorders. Drugs. 57, 583 (1999) https://doi.org/10.2165/00003495-199957040-00009
- Jean-Paul, D. : Clinical implications of the biopharmaceutical properties of fluvastatin. The American Journal of Cardiology 73, 12 (1994)
- Fische, V., Johanson, L. and Heitzl, F. : The 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug. Metab. Dispos. 27, 410 (1999)
- Cohen, L. H., van Leeuwen, R. E., van Thiel, G. C. van Pelt, J. F. and Yap, S. H. : Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm. Drug. Dispos. 21, 353 (2000) https://doi.org/10.1002/bdd.249
- Kirchheiner, J. and Brockmoller, J. : Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77, 1 (2005) https://doi.org/10.1016/j.clpt.2004.08.009
- Kirchheiner, J., Kudlicz, D., Meisel, C., Bauer, S., Meineke, I., Roots, I. and Brockmöller, J. : Influence of CYP 2C9 polymorphisms on the pharmacokinetics and cholesterollowering activity of (-)-3s,5r-fluvastatin and (+)-3r,5s-fluvastatin in healthy volunteers. Clinical Pharmacology & Therapeutics. 74, 186 (2003) https://doi.org/10.1016/S0009-9236(03)00121-8
- Yeo, K. R. and Yeo, W. W. : Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br. J. Clin. Pharmacol. 51, 461 (2001) https://doi.org/10.1046/j.1365-2125.2001.01386.x
- Watanabe, H., Kosuge, K., Nishio, S., Yamada, H., Uchida, S., Satoh, H., Hayashi, H., Ishizaki, T. and Ohashi, K. : Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci. 76, 281 (2004) https://doi.org/10.1016/j.lfs.2004.06.022
- Bogman, K., Peyer, A. K., Torok, M., Kusters, E. and Drewe, J. : HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol. 132, 1183 (2001) https://doi.org/10.1038/sj.bjp.0703920
- Ehrhardt, M., Lindenmaier, H., Burhenne, J., Haefeli, W. E. and Weiss, J. : Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochemical Pharmacology 67, 285 (2004) https://doi.org/10.1016/j.bcp.2003.09.008
- Goebel, K. J. and Kolle, E. U. : High performance liquid chromatographic dertermination of diltiazem and four of its metabolites in plasma. J. Chromatogr. 345, 355 (1985) https://doi.org/10.1016/0378-4347(85)80172-9
- Rocci, M. L. and Jusko, W. J. : LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine. 16, 203 (1983) https://doi.org/10.1016/0010-468X(83)90082-X
- Mc Donnell, C. G., Shorten, G. and Van Pelt, F. N. : Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia. 60, 747 (2005) https://doi.org/10.1111/j.1365-2044.2005.04110.x